MedTrace Logo

The Use of Cell Free Fetal DNA in the Maternal Blood in the Evaluation of Intrauterine Fetal Demise and Miscarriage

NCT01916928 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2017-03-13

Study results available
· View outcomes & findings →

Summary

Women presenting to Washington Hospital Center with fetal loss would be offered participation in the study. The objective is to determine if ccffDNA obtained from maternal blood is present in the setting of missed abortion or fetal demise.

The investigators primary hypothesis is that cell free fetal DNA will be present in maternal blood in the presence of a failed pregnancy.

Conditions

  • Circulating Cell Free Fetal DNA
  • Intrauterine Fetal Demise
  • Miscarriage

Sponsors & Collaborators

  • Sequenom Laboratories

    collaborator UNKNOWN

  • Medstar Health Research Institute

    lead OTHER

Principal Investigators

  • Rita W Driggers, MD · Medstar Health Research Institute

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2014-01-31
Completion
2014-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01916928 on ClinicalTrials.gov